# Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

> **NCT02533375** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 10 (actual)

## Conditions studied

- Generalized Pustular Psoriasis (GPP)
- Adalimumab
- Japanese

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02533375
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2016-09-15
- **Final completion:** 2017-07-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533375, "Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02533375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*